Theralase Technologies (FRA:TTX) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TTX Theralase Technologies Inc FRA:TTX
51 GF Score
Price €0.11
GF Value €0.10
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Theralase Technologies Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

FRA:TTX
51GF Score
Theralase Technologies Inc FRA:TTX
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theralase Technologies (FRA:TTX) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of €0.11 is trading 11% above its estimated GF Value™ of €0.10. GuruFocus considers Theralase Technologies to be Modestly Overvalued.

Key valuation signals for FRA:TTX:

  • Dividend-Payout-to-FFO:
  • GF Value™: €0.10 vs. price of €0.11 (11% above fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the FRA:TTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TLTFF:USATLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc. is a Canadian life sciences company focused on light-activated technologies for cancer treatment and pain therapy. It operates through two divisions. The Drug Division develops patented photo dynamic compounds (PDCs) that are activated by proprietary laser technology to destroy targeted cancers, bacteria, and viruses; its lead program is a intravesical photodynamic therapy for non-muscle invasive bladder cancer. The Device Division designs, manufactures, and markets super-pulsed laser technology cleared by Health Canada and the U.S. Food and Drug Administration for healing chronic knee pain, with the technology also used off-label for nerve, muscle, and joint conditions. The company generates revenue primarily from sales of its therapeutic laser devices and related accessories, while its drug development activities remain in clinical-stage research. Theralase serves healthcare practitioners and patients, mainly in Canada and the United States.
51GF Score

Get the complete analysis for FRA:TTX

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.11
Price
€0.10
GF Value